key: cord-1021404-ps2qazgt
authors: Castelo-Branco, Luis; Awada, Ahmad; Pentheroudakis, George; Perez-Garcia, Jose Luis; Mateo, Joaquin; Curigliano, Giuseppe; Banerjee, Susana; Giuliani, Rosa; Lordick, Florian; Cervantes, Andres; Tabernero, Josep; Peters, Solange
title: Beyond the lessons learned from the Covid19 pandemic: Opportunities to optimize clinical trial implementation in oncology
date: 2021-07-24
journal: ESMO Open
DOI: 10.1016/j.esmoop.2021.100237
sha: c68aa851f852b34c3fcf041622e7978e9215ebf5
doc_id: 1021404
cord_uid: ps2qazgt

The COVID-19 pandemic affected millions of people globally with lasting effects on society, patients, investigators and health institutions. Clinical trials, our best tool to improve cancer treatment for patients through testing the clinical value of a new treatment, have been affected by the pandemic. The pandemic footprint represents both a risk of compromising development of new therapies and an opportunity to elicit discussion over a portfolio of broader reforms, applicable irrespective of pandemics, in order to improve the design and implementation of clinical trials in oncology. The administrative load should be reduced, without affecting the quality of research and principles of good clinical practice. Cancer centres are encouraged to adapt their research/operational structures to the requirements of molecular oncology and embrace novel trial designs. Technological and methodological leaps in telemedicine can convert physical to virtual visits while routine examinations may be performed in local institutions (co-research centres), maintaining adherence to good clinical and research practices. The adoption of broader inclusion criteria and clinically significant endpoints (survival, quality of life) should be promoted, co-existing with pathways for fast-track “conditional” drug approvals in areas of unmet need, based on surrogate endpoints that are linked to strict post-approval validation requirements. The utility of Real World Data as part of these validation requirements should be actively investigated. Lessons learnt from the SARS Cov2 pandemic can be developed in order to expand equitable access to clinical trials of a real world population, in a simplified and methodologically robust modus operandi, for the benefit of all our patients.

Since the beginning of 2020, the COVID-19 pandemic has progressively affected millions of people worldwide and has brought many uncertainties for patients, health Published evidence consistently shows that cancer patients are at higher risk of death from COVID-19 (2) (3) (4) . In the first months of the pandemic, all levels of care (screening, diagnosis, treatment, and follow-up) were disrupted (5) (6) (7) . Moreover, cancer centres started prioritizing care services, cancelling non-urgent appointments, adapting treatment protocols and shifting to home-based remote care relying on telemedicine J o u r n a l P r e -p r o o f consultations (5, 7) . The deferral of screening programs and cancer-directed interventions generates concerns for an increase in the number of patients diagnosed with advanced disease stage and poor outcomes (6) (7) (8) (9) (10) (11) (12) .

In these unprecedented circumstances, healthcare institutions, researchers and policymakers adapted quickly with variably coordinated responses worldwide. Along with vaccine development and research for COVID-19 therapies, international collaborative registries such as the ESMO-CoCARE (13) or CCC19 (14) initiatives were set-up in record time with the aim to gather evidence from patients with cancer infected with SARS-CoV-2. Additionally, many societies such as ESMO and ASCO published recommendations in order to provide guidance for cancer institutions, oncologists and patients (15) (16) (17) . However, this crisis also highlighted the need to optimize the delivery of care and the use of resources in clinical research. In this paper, we aim to capitalize on the lessons learnt from the impact of the COVID-19 pandemic on clinical trials and use them as a catalyst in order to launch a discussion over a framework of broader adaptations needed in the design and implementation of oncology clinical trials.

Even before the COVID-19 pandemic, important barriers impacted on the conduct of clinical trials (18) (19) (20) . Different research groups have been proposing a number of solutions in order to remedy the complex, and at times dysfunctional reality of clinical cancer research (19) (20) (21) (22) . To add to this background, clinical research activities were seriously impaired at the beginning of the SARS-CoV-2 pandemic resulting in many sites struggling to maintain their trial activity and to start new studies (18, (23) (24) (25) .

Recruitment of new patients and follow-up visits were reduced with the advent of lockdown measures in most places (26, 27) , while the pandemic and quarantine policies affected significantly research staff availability and performance. In a survey conducted by the ESMO Resilience Task Force in oncology professionals (n=1520), 67% of responders reported a change in professional duties since COVID-19, 66% were not able to perform their job compared with the pre-COVID-19 period and 38% experienced burnout symptoms (28) .

J o u r n a l P r e -p r o o f As a consequence, the launch of new clinical trials, screening and enrolment of new patients, clinical visits, updates of case report forms (CRF) were affected (23, 25, 26, 29) .

The pandemic also hindered patient empowerment ("decision making process") due to the distancing between investigators, caregivers, patients, and families. In fact, several background problems for clinical trial research became even more difficult to manage during the COVID-19 pandemic (Table 1) .

The need for adjustments in clinical trial procedures prompted the European Medicines Agency (EMA) and American Food and Drug Administration (FDA) to publish guidance during the COVID-19 pandemic (29, 30) . At the same time trial sponsors adapted protocols with a series of amendments, including the need to "reconsent for trial enrolment during COVID-19". Sponsors, investigators, and patients improvised with adaptation strategies while experts and scientific societies highlighted the need and opportunity to rethink how clinical trials are run (18, (31) (32) (33) (34) . In Table 2 we recapitulate the educative lessons to be considered for the future of clinical research post COVID-19 (Table 2) .

In a recent survey by the ESMO Clinical Research Observatory (ECRO), clinical investigators (n =940) strongly agreed on the excessive burden of administrative tasks that reflect negatively on the quality of clinical research (19) . While adherence to international guidelines such as the Helsinki Declaration and Good Clinical Practice demanding. These factors decrease investigator motivation, hinder drug development and patient´s access to innovative treatments. (19, 21, 35) . This background problem became more complex to manage as the pandemic started affecting health institutions, forcing research sponsors to revisit their internal procedures to facilitate implementation of clinical trials.

Well-conducted studies require resources, trained investigators, and dedicated teams.

Lack of preparedness and mechanisms for flexible adaptation of these elements affected several research centres and contributed to the significant reduction in clinical trial activity (25, 36) . Organizations should develop a clear resilience plan to be implemented during challenging conditions (such as the pandemic), bringing together investigators, administrators, and patients for its development in a base to apex approach. Digital technologies and remote data collection/review approaches are integrative in such contingency plans.

Data monitoring events, local meetings and audits are very demanding activities for sponsors and researchers (19) (20) (21) and although necessary, they can be trimmed and be performed remotely, without compromising the integrity and quality of clinical research. This was successfully tested during the pandemic and could be continued in the future (36) (37) (38) (39) . Remote meetings, data verification and monitoring (phone calls, video visits, emails) of data collected from each clinical trial site may be permitted in appropriately defined settings, after validated standard operating procedures are set in place. In addition, artificial intelligence (AI) tools and text-mining technologies for data collection, review and monitoring, when properly validated, could be used to reduce the burden of work needed by a human hospital operator (40) (41) (42) . 

The informed consent (IC) is a cornerstone trial feature empowering patients and relatives with the most relevant information for their own decisions. With current practices it is often too complex, long, having excessive medical jargon and time demanding both for patients and investigators (43, 44) . Also, IC amendments are frequently required, and both patients and researchers need to go through a timeconsuming process of reconsent. As the pandemic surged worldwide, sponsors rapidly adapted their trials with amendments, resulting in more person visits for reconsents.

Over time, remote consents, which were not common before the pandemic, became progressively permitted either by videoconference (oral consent) or via electronic records and signatures. With modern technology and electronic security mechanisms in place, a remote consent (or re-consent) could be maintained post pandemic, particularly for patients having difficulties to access the research centre. However, provisions for face-to-face meetings and authorizations should be made possible, specifically if requested by the patient. The trend for more remote consents raises the need to develop specific eConsent guidelines and validation studies with close monitoring to ensure patient empowerment, efficiency and data security (45) . An implementation process is needed to provide information on how to determine whether eConsent is a feasible approach, which multimedia components are a reasonably good fit for a specific study, and the external and internal data security/audit processes to consider when implementing.

In order to improve patient and relatives literacy in clinical research, dedicated sources of information should be developed. Web-based networks and compassionate communities can foster dialogue between patients and promote the exchange of information as well as literacy, participation and compliance with clinical trials (46) (47) (48) .

Finally, new opportunities to improve and simplify ICs such as applying readability J o u r n a l P r e -p r o o f methodologies (49) , shortening documents and engaging patient´s advocates in IC development, will optimise patient empowerment.

Different studies have reported significant dropout rates of cancer patients in clinical trials (50) (51) (52) .The extensive paperwork, number of visits, examinations might demotivate many patients and investigators from complying with intensive research protocols. These obstacles increased during the pandemic (53) with many patients selfisolating and dropping out from trials (26, 27) . For all these clinical and laboratory pathways, there must be an agreement between patients, research centres and the sponsor, with scientific and financial incentives provided for local and regional centres by the latter. For laboratory examinations, it J o u r n a l P r e -p r o o f should be formally certified that the same methodologies and units are used, and data are easily interoperable, accessed or sent to the main research centre. Imaging modalities may also be decentralised, provided a standardised protocol is used for image acquisition, all exams are digitized, stored securely, anonymised, and easily accessed by the main research centre. Only essential study procedures, such as biomarker assessments or tumour biopsies, should be validated centrally for good scientific reasons (54) . Additionally, in many countries and hospitals the delivery of cancer medication to patient´s home expanded to more patients, clinical conditions, and drugs as a response to the pandemic. While not yet generalized in clinical trials, this could be considered in future for some oral treatments, after setting up proper protocols for drug delivery, accountability, and compliance monitoring. Novel electronic patient reported outcome (ePROs) strategies could be used to collect patient-level reliable data, while reducing the number of physical appointments. These may include quality of life (QoL) scales and use of wearable devices, phone apps or online reports (59, 60) . The use of these remote monitoring tools can enable symptom J o u r n a l P r e -p r o o f management to be performed either remotely or locally at the patient´s home. However, more research is needed before all these tools are properly validated to be considered in clinical trials, and this avenue should be pursued (61) . To date, evidence of benefits of digital symptom monitoring has been largely focused on patients receiving treatment for metastatic cancer. There has been scant evaluation of impact on patients with curable disease receiving time-delimited adjuvant therapy who have minimal disease burden and symptoms.

The scientific community have been identifying several challenges and opportunities to improve cancer clinical research (20, (62) (63) (64) . Before the pandemic, the restrictive eligibility criteria and under-representation of real-world population was already considered a potential deficit in clinical trials (51, 65) . Elderly patients and those with severe comorbidities, abnormal laboratory profiles or moderate performance status are commonly excluded from pivotal research, although they represent a significant proportion of the real-world cancer population (65) (66) (67) (68) (69) .

Another important challenge for cancer research has been the definition of endpoints capturing relevant outcomes in each research setting as timely as possible, in order to provide the patient with rapid access to innovative therapeutics. Ideally, surrogate endpoints with strong correlation with clinically meaningful outcomes should serve this purpose, but few comply to this definition (70) (71) (72) . As an example, after granted accelerated approval for several Immune Checkpoint Inhibitors, FDA announced that four indications were voluntarily withdrawn, and six others were under review since reported results from confirmatory trials have not verified clinical benefit (73) .

Consequently, surrogate endpoints, as important as they are to rapidly bring innovative treatments to patients with cancer, need to be validated in each context for their correlation with clinically meaningful outcomes, such as improvement of overall survival and/or quality of life, in the setting of clinical trials. Real world data may be extremely important to validate such correlations in contexts in which trials are unethical (unmet need, no effective therapy) or not feasible (rare tumours).

In an analogous experience, the pandemic emergency led to the launch of several clinical research projects, vaccines were developed and approved in record time and J o u r n a l P r e -p r o o f many real world evidence (RWE) studies were published. Shorter-term endpoints were used in COVID-19 trials, resulting in marketing authorisation of several effective vaccines. However, relevant endpoints such as the long term vaccine protection, interruption of virus transmission and rare events were not considered, some population groups ( cancer, immunosuppression, adolescents) were not included, resulting in knowledge gaps (74) . To partly remedy this, close monitoring with trials and real-world studies further confirmed vaccine effectiveness (75, 76) while safety signs were captured in time by pharmacovigilance systems (77, 78) . Nevertheless, there were also contradictory evidence from different real-world studies assessing some treatments against COVID-19 such as with chloroquine or remdesivir, due to variations in local management, data quality and granularity.

The SARS Cov 2 vaccine trial experience, and overall the challenges encountered in clinical trial activities due to the stress imposed by a viral pandemic, should become the catalyst for initiating a multi-stakeholder discussion on broader reforms in the design, organisation and implementation of clinical research in oncology. Inefficiencies highlighted by the pandemic can become opportunities to elicit carefully designed adaptations aiming to improve 1-representativeness of trial populations, 2-balanced use of accelerated drug approvals based on surrogate endpoints, 3-validation of benefits from new drugs captured by surrogate endpoints in clinically relevant outcomes in trials and real world data (79, 80) . Both before and certainly after the pandemic, we advocate for trials with relevant, patient-centered and clinically meaningful endpoints, in representative populations as similar as possible to real world settings, while acknowledging the need for fast-track patient access to promising novel therapeutics.

When proof of remarkable benefit is provided by a novel treatment in an area of unmet need in the setting of a clinical trial using surrogate endpoints, fast conditional approval can be justified, coupled to future validation in confirmatory studies (clinical trials supplemented with real-word data) assessing mature, clinically meaningful, 'hard' endpoints. In this setting, the role of real world data as a synergistic and complementary research methodology to traditional randomised trials should be further assessed after building consensus on significant methodology and quality requirements (63) .

The pandemic impact sorely stressed the need to study optimal paths for delivering these goals. Mechanisms such as the PRIME scheme launched by EMA to enhance J o u r n a l P r e -p r o o f support for the development of medicines that target an unmet medical need could be expanded, with periodic re-assessment (81) . The development of artificial intelligence tools offers promise for the empowerment of real-world data in the assessment of therapeutics and biomarkers, however they should be rigorously validated before general use.

The COVID-19 pandemic affected millions of people globally, and its effects on society, patients, health institutions and governments may persist. Clinical trials are our best tool to improve cancer treatment for patients through testing the clinical value of a new treatment or intervention; however, they were particularly affected by the COVID pandemic, despite frantic adjustments. Still, the challenges imposed by the pandemic on daily running of clinical trials in oncology highlighted pre-existing inefficiencies.

The pandemic and its impact should be revisited as an opportunity and catalyst to ignite a discussion among all stakeholders on pragmatic reforms that will transcend through and expand beyond pandemic lessons, ultimately aiming to improve cancer clinical research in all contexts. The clinical trial administrative load could be significantly 

Apogen and Pfizer; and institutional financial support (clinical trials, Italy) from MSD and Novartis

He reports honoraria as Invited Speaker

He reports he serves as Associate Editor Annals of Oncology, Editor Cancer Treatment Reviews. He reports Research Grant as PI (paid to institution): Abbvie, Actuate Therapeutic

Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc. He reports Educational Collaboration: Imedex, Medscape Education, MJH Life Sciences

She reports receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen

Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: A matched cohort study using linked English electronic health records data

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet

COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry

Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors

Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study

Oncology Practice During the COVID-19 Pandemic

Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic

The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study

Mortality due to cancer treatment delay: systematic review and meta-analysis

The impact of the COVID-19 pandemic on cancer care. Nat Cancer

LBA76_PR Expected medium and long term impact of the COVID-19 outbreak in oncology

CCC19. The COVID-19 and Cancer Consortium

COVID-19 and Cancer

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

ASCO Coronavirus Resources

Rethinking cancer clinical trials for COVID-19 and beyond. Nat Cancer

ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. ESMO Open

Bureaucracy is strangling clinical research

Reducing Bureaucracy in Clinical Research: A Call for Action. HemaSphere

Data protection and research in the European Union: a major step forward, with a step back

Impact of the COVID-19 pandemic on clinical research

Cuts in cancer research funding due to COVID-19

Trends in Oncology Clinical Trials Launched Before and During the COVID-19 Pandemic

Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials

Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. ESMO Open

FDA Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency

COVID-19 pandemic and impact on cancer clinical trials: An academic medical center perspective

Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? ESMO Open

Preserving Clinical Trial Integrity During the Coronavirus Pandemic

Lessons learned from COVID-19 for clinical research operations in Italy: what have we learned and what can we apply in the future?

Contract Research Agonizations

Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an

Remote Monitoring in Clinical Trials During the COVID-19 Pandemic

Digitalized Adaptation of Oncology Trials during and after COVID-19

Rethinking Clinical Trials Reform During the COVID-19 Pandemic

Artificial intelligence in oncology

A Systematic Review of Artificial Intelligence in Prostate Cancer

Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discov

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

Enduring and Emerging Challenges of Informed Consent

Replacing Paper Informed Consent with Electronic Informed Consent for Research in Academic Medical Centers: A Scoping Review

Compassionate communities and end-of-life care

The effectiveness of health literacy interventions on the informed consent process of health care users: a systematic review protocol

Health Literacy: From a Property of Individuals to One of Communities

Guideline on the readability of the labelling and package leaflet of medicinal products for human use

Drop-out rates of cancer patients participating in longitudinal RCTs

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

Exploring non-retention in clinical trials: a metaethnographic synthesis of studies reporting participant reasons for drop out

Impact of COVID-19 on clinical trials and clinical research: A systematic review

HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

Telehealth transformation: COVID-19 and the rise of virtual care

Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives

Keep Calm and Log On: Telemedicine for COVID-19 Pandemic Response

Guideline for Establishing and Maintaining Sustainable Telemedicine Services in New Zealand

A systematic review of feasibility studies promoting the use of mobile technologies in clinical research

Improving Cancer Care Through the Patient Experience: How to Use Patient-Reported Outcomes in Clinical Practice

Use of Wearable, Mobile, and Sensor Technology in Cancer Clinical Trials

Rethinking cancer: current challenges and opportunities in cancer research

Randomized Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative

The global challenge of cancer. Nat Cancer

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Underrepresentation of the elderly in clinical trials, time for action

Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-<em>Friends</em> of Cancer Research Performance Status Work Group

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines

FDA In Brief: FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval [Internet]. FDA

Will covid-19 vaccines save lives? Current trials aren't designed to tell us

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. medRxiv

Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

Food and Drug Administration O of the. Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review

EMA -European Medicines Agency. Conditional marketing authorisation

PRIME: priority medicines